<table border="1" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Drugs Having Clinically Important Interactions with Amphetamines</caption>
<col width="72.9pt"></col>
<col width="405.9pt"></col>
<tbody>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules concomitantly or within 14 days after discontinuing MAOI <content stylecode="italics">[see <linkhtml href="#LINK_81c812da-523b-4e4c-bfe1-71ab1f5844e8">CONTRAINDICATIONS (4)</linkhtml> and <linkhtml href="#LINK_c82fd884-2a86-424f-ad59-d5c01ac35550">WARNINGS AND PRECAUTIONS (5.6)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules and serotonergic drugs increases the risk of serotonin syndrome.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules and the concomitant serotonergic drug(s) <content stylecode="italics">[see <linkhtml href="#LINK_c82fd884-2a86-424f-ad59-d5c01ac35550">WARNINGS AND PRECAUTIONS (5.6)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. Johnâ€™s Wort</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">CYP2D6 Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>The concomitant use of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules and CYP2D6 inhibitors may increase the exposure of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules compared to the use of the drug alone and increase the risk of serotonin syndrome.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules and the CYP2D6 inhibitor <content stylecode="italics">[see <linkhtml href="#LINK_c82fd884-2a86-424f-ad59-d5c01ac35550">WARNINGS AND PRECAUTIONS (5.6)</linkhtml> and <linkhtml href="#LINK_32e2e95c-d434-478e-8988-a76473d3c2f7">OVERDOSAGE (10)</linkhtml>].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Alkalinizing Agents</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Increase blood levels and potentiate the action of amphetamine.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Co-administration of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules and gastrointestinal or urinary alkalinizing agents should be avoided.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Gastrointestinal alkalinizing agents (e.g., sodium bicarbonate). Urinary alkalinizing agents (e.g. acetazolamide, some thiazides).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Acidifying Agents</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Lower blood levels and efficacy of amphetamines.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Increase dose based on clinical response.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid). Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Tricyclic Antidepressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor frequently and adjust or use alternative therapy based on clinical response.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>desipramine, protriptyline</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Toprule     ">
<paragraph>
<content stylecode="bold">Proton Pump Inhibitors</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Clinical Impact</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Intervention</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>Monitor patients for changes in clinical effect and adjust therapy based on clinical response.</paragraph>
</td>
</tr>
<tr>
<td stylecode="     Toprule     ">
<paragraph>Examples</paragraph>
</td>
<td stylecode="     Toprule         Lrule     ">
<paragraph>omeprazole</paragraph>
</td>
</tr>
</tbody>
</table>